Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEOPRISM-CRC: Neoadjuvant Pembrolizumab in Colorectal Cancer
NCT05197322Phase 2Active, not recruiting
- Sponsor
- University College London
- Start
- Jul 2022
- Primary completion
- Nov 2029
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of pembrolizumab in colorectal cancer (CRC) (2 arms), sponsored by University College London. Primary endpoint: Relapse-free survival up to 3 years. Started Jul 2022; status: active, not recruiting.
02
Drugs
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT05197322.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05197322.